Discontinuation rates: who actually stays on treatment
Joseph Lambson discusses risks on Its (Probably) Not Rocket Science, highlighting issues with compounded semaglutide and non-prescription purchases
These are not identical studies, so cross-trial comparison should be treated as directional rather than definitive
Tirzepatide is not indicated for type 1 diabetes and should not be used in combination with other GLP-1 receptor agonists or weight management medications
(2) Long-term Results : Studies indicate lasting results even after stopping the medication, providing patients with tools for long-term weight maintenance
You still get appetite regulation, improved insulin sensitivity, and steady fat loss, but with significantly fewer side effects and a much lower risk of the muscle wasting that concerns people at higher doses